1.ACE Inhibitors and Losartan in the Managerment of Hypertesion.
Korean Circulation Journal 1998;28(1):5-7
No abstract available.
Angiotensin-Converting Enzyme Inhibitors*
;
Losartan*
2.Angiotensin converting enzyme inhibitors remain the first treatment of choice.
Pyung Chun OH ; Ichiro SAKUMA ; Toshio HAYASHI ; Kwang Kon KOH
The Korean Journal of Internal Medicine 2016;31(2):237-241
No abstract available.
*Angiotensin-Converting Enzyme Inhibitors
;
Humans
3.Review of role of the angiotensi converting enzyme inhibitors
Journal of Practical Medicine 2000;383(6):22-24
Angiotensin converting enzyme inhibitors have a good effects for patients with primary hypertension and in solving some outcomes of the diseases leading to left ventricular insuffiency. The mechanism of the drugs is to bind zinc ion of angiotension converting enzyme. Therefore, the effect of converting angiotensin I into angiotension II was lost. Angiotension II has effect of the smooth muscle stimulation, aldosterone excretion, hemodynamic change, catecholomine release and glucocorticoid exeretion.
Angiotensin-Converting Enzyme Inhibitors
;
Pharmaceutical Preparations
4.Angiotensin Converting Enzyme Inhibitors for the.
Journal of the Korean Pediatric Cardiology Society 2001;5(2):115-127
No Abstract available.
Angiotensin-Converting Enzyme Inhibitors*
;
Angiotensins*
;
Peptidyl-Dipeptidase A*
5.The association of withdrawing maintenance renin-angiotensin system inhibitor on all cause mortality and intensive care unit admission among hypertensive patients admitted for mild to moderate COVID-19 infection: A meta-analysis of observational studies
Arlene Melissa T. Dychiching ; Erwin D. Dizon
Philippine Journal of Cardiology 2024;52(1):45-50
INTRODUCTION:
The pandemic caused by coronavirus disease 2019 (COVID-19) posed a serious challenge to all health care systems in the world. It has been found to be harmful in people with underlying cardiovascular diseases, particularly in patients with systemic hypertension, which may be due to upregulation of angiotensin-converting enzyme 2 (ACE2) expression, which may lead to increased severe acute respiratory syndrome coronavirus 2 virulence. Renin-angiotensin system inhibitor (RASI) acts by blocking the angiotensin-converting enzyme and angiotensin II type 1 receptors, which in turn affects the production of the ACE2 protein. Hence, there have been arguments on whether to continue or discontinue this medication. Given the widespread use of RASIs globally and the fact that they are generally cardioprotective, research into the safety of continuing these maintenance medications in patients hospitalized with mild to moderate COVID-19 is immensely needed.
METHODS:
This meta-analysis involved review of observational studies among hypertensive patients on maintenance ACE inhibitor or angiotensin-receptor blocker with confirmed mild to moderate COVID-19 infection. Analyses were performed to determine the adjusted hazard ratio of each event using the raw data obtained from each study. Random-effects model and Cochran-Mantel-Haenszel method were utilized at 95% confidence interval. To check for heterogeneity, χ2 test and I2 statistic were calculated. Cochrane ReviewManager (RevMan version 5.3) was used for data analysis, and forest plots were generated.
RESULTS:
At 95% confidence interval, the adjusted hazard ratios for all-cause mortality and intensive care unit (ICU) admission at 95% confidence interval were 1.64 (1.22, 2.21) and 1.93 (1.34, 2.79), respectively. The tests of overall estimate effect for both outcomes were P < 0.0001 for all-cause mortality and P = 0.0003 for ICU admission.
CONCLUSION
Discontinuation of maintenance RASI during hospitalization is associated with increased all-cause mortality and ICU admission among hypertensive patients with mild to moderate COVID-19 infection.
Angiotensin-Converting Enzyme Inhibitors
;
Coronavirus:COVID-19
6.Enzymatic hydrolysis of antler and properties of hydrolysates.
Fan ZHENG ; Renkuan LI ; Huilin WANG ; Junming ZHUANG ; Xiuyun YE
China Journal of Chinese Materia Medica 2010;35(19):2628-2633
Lyophylized antler powder was hydrolyzed by pepsin and trypsin separately and also simultaneously to give hydrolysates with special physical activities. Complete hydrolysis peptides with MW lower than 1 x 10(3) were collected for assay of angiotensin I-converting enzyme (ACE) inhibitory activity, antioxidant activity and proliferative activity toward UMR-106 osteoblast cells. The results of the experiments revealed that all hydrolysates exhibited potent hydroxyl radical scavenging activity with an IC50 value less than 1 mg/ml which was much lower than the value of 5.5 g x L(-1) for vitamin C. The peptic and peptic tryptic hydrolysates demonstrated strong angiotensin I-converting enzyme (ACE) inhibitory activity. The tryptic hydrolysate increased the proliferation of the UMR-106 cells by 73.43%. The results verified the traditional use of antler in bone-strengthening, anti-aging. The exploratory studies on the ACE inhibitory activity of antler hydrolysates indicated that the hydrolysates might be potentially useful in prevention and treatment of hypertension. Further purification of peptides contributing to the antioxidant activity, angiotensin I-converting enzyme-inhibitory activity and proliferative activity toward osteoblasts from antler hydrolysates is warranted.
Angiotensin-Converting Enzyme Inhibitors
;
metabolism
;
Animals
;
Antioxidants
;
metabolism
;
Antlers
;
chemistry
;
metabolism
;
Biphenyl Compounds
;
metabolism
;
Cell Proliferation
;
drug effects
;
Deer
;
Endopeptidases
;
metabolism
;
Free Radical Scavengers
;
Hydrolysis
;
Hypertension
;
chemically induced
;
Pepsin A
;
metabolism
;
Peptides
;
pharmacology
;
Peptidyl-Dipeptidase A
;
metabolism
;
Picrates
;
metabolism
;
Trypsin
;
metabolism
7.Systematic evaluation of efficacy and safety of Songling Xuemaikang Capsules in treatment of essential hypertension.
Gen-Hao FAN ; Zuo-Ying XING ; Meng-Lin LIU ; Yan CHEN ; Yi-Pei AN ; Zhao-Qi CHEN ; Yong-Xia WANG
China Journal of Chinese Materia Medica 2021;46(2):467-477
To evaluate the efficacy and safety of Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. PubMed, VIP, CNKI, Wanfang and other databases were retrieved from the establishment of the database to February 2020 for clinical randomized controlled trial(RCT) about Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. The literatures were screened out according to the inclusion criteria, and RevMan 5.3 software was used for Meta-analysis. A total of 3 100 patients in 27 RCTs were enrolled. According to Meta-analysis, Songling Xuemaikang Capsules combined with conventional Western medicine could effectively reduce systolic blood pressure(MD=-7.88,95%CI[-9.68,-6.08],P<0.000 01) and diastolic blood pressure(MD=-7.85, 95%CI[-9.07,-6.62], P<0.000 01), triglyceride(MD=-0.46, 95%CI[-0.66,-0.26], P<0.000 01) and total cholesterol(MD=-0.92, 95%CI[-1.49,-0.35], P=0.001), but increase HDL cholesterol(MD=0.51, 95%CI[0.28, 0.73], P<0.000 01), with a better effect than the Western medicine group alone. The results of LDL-C analysis showed that there was no significant difference between the two groups(MD=-0.91, 95%CI[-1.82, 0.01], P=0.05). The subgroup analysis suggested that reduced systolic blood pressure may be related to the use of ARB. There was a close correlation between CCB drugs and the decrease of diastolic blood pressure. In addition, there was no significant difference in the compliance and the incidence of adverse reactions. Clinical application of Songling Xuemaikang Capsules combined with Western medicine in the treatment of patients with essential hypertension has clear efficacy and certain safety. More clinical randomized controlled trials are needed for verification in the future.
Angiotensin Receptor Antagonists
;
Angiotensin-Converting Enzyme Inhibitors
;
Capsules
;
Drugs, Chinese Herbal
;
Essential Hypertension/drug therapy*
;
Humans
8.Construction of pharmacophore model of PARP-1 inhibitor.
Wen-Ting ZHANG ; Hao YAN ; Feng-Chao JIANG
Acta Pharmaceutica Sinica 2007;42(3):279-285
To construct the pharmacophore model of the poly (ADP-ribose) polymerase-1 inhibitor and to investigate the possible inhibitory mechanisms, ten pharmacophore models of PARP-1 inhibitor were established from the training set of thirty-eight PARP-1 inhibitors with conformer analysis and pharmacophore mapping by using the Catalyst software. Based on the mechanism of action and the known structure-activity relationship of PARP-1 inhibitor, an optimal pharmacophore model including two hydrogen-bonding acceptors and two aromatic hydrophobic core was confirmed. The reliability of the optimal pharmacophore model is preferably with RMS = 0.46, Correl = 0.91, Weight = 2.06, and Config = 15.97. This pharmacophore model not only provided some information about the interaction between enzyme and compound, but also showed excellent forecast ability and contributes to design the PARP-1 inhibitors with undiscovered structure.
Computer-Aided Design
;
Drug Design
;
Enzyme Inhibitors
;
chemistry
;
pharmacology
;
Models, Molecular
;
Molecular Structure
;
Poly (ADP-Ribose) Polymerase-1
;
Poly(ADP-ribose) Polymerase Inhibitors
;
Poly(ADP-ribose) Polymerases
;
chemistry
;
Protein Conformation